ThomasAnthonyCiullaMDMBA

Ophthalmology • Indianapolis, IN

Retinal Disease

Retina Specialist, Midwest Eye Institute, Indianapolis, IN

Join to view full profile

Dr. Ciulla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ciulla's full profile

Already have an account?

Office
Midwest Eye Insitute
10300 North Illinois Street
Indianapolis, IN 46290
Phone+1 317-817-1822

Fax+1 317-817-1898

Summary

I am a board certified ophthalmologist and retina specialist, who graduated from Harvard College and from the University of California San Francisco School of Medicine, followed by a residency in Ophthalmology at Harvard Medical School, and then a fellowship in Vitreo-Retinal Diseases and Surgery at Tufts Medical School, Boston.

I co-directed the Retina Service and Ocular Angiogenesis Research Lab at Indiana University School of Medicine, one of the largest U.S. medical schools, prior to joining Midwest Eye Institute, one of the largest subspecialty eye institutes in the Midwest. In 2015, I earned an MBA from Indiana University’s Kelley School of Business, specializing in the business of medicine, and assumed industry leadership roles of increasing responsibility, as VP at Iveric Bio; VP at Spark Therapeutics to support development and commercialization of Luxturna, the first FDA-approved gene therapy for a genetic disease; and Chief Medical Officer at Clearside Bio. I remain a Volunteer Clinical Professor of Ophthalmology.

I serve on the Editorial Board of several ophthalmology journals, and remain an active member of the Association for Research in Vision and Ophthalmology, Macula and Retina Societies, the American Academy of Ophthalmology, the American Society of Retina Specialists, and The American Society of Gene and Cell Therapy.

I have held numerous leadership roles in clinical research, serving as principal investigator, medical monitor, and member of scientific advisory, data safety monitoring or writing committees in over 100 national clinical trials, including trials that led to FDA approval of several new retinal therapies. I have delivered over 200 presentations nationally and internationally, edited textbooks, and co-authored nearly 150 Medline-indexed peer reviewed publications, including the first U.S.-based randomized clinical trial on any intravitreal therapy in neovascular AMD.(https://www.ncbi.nlm.nih.gov/pubmed/10872928)

Education & Training

Indiana University, Kelley School of BusinessMBA, Business of Medicine, Beta Gamma Sigma Honor Society, 2013 - 2015
Tufts Medical CenterFellowship, Surgical Retina and Vitreous, 1995 - 1996
Massachusetts Eye and Ear Infirmary, Harvard Medical School1992 - 1995
B I Deaconess Med Ctr1991 - 1992
University of California San Francisco School of MedicineClass of 1991
Harvard CollegeB.A, Chemistry, 1982 - 1986

Certifications & Licensure

IN State Medical License 1996 - 2025
MA State Medical License 1993 - 2004
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Indianapolis Monthly Castle Connolly, 2013
Best Paper” Award Treatment of Macular Edema Following Central Retinal Vein Occlusion with Pegaptanib Sodium (Macugent): A One-Year Study, 2007
American Academy of Ophthalmology 2007 Annual Meeting Scientific Program, 2007
Honor Award American Society of Retinal Specialists, 2004
Achievement Award American Academy of Ophthalmology, 2003
Career Development Award, 1999-2002 Research to Prevent Blindness, 2002
Best Doctors in Indianapolis Retina-Vitreous/Ophthalmology, Indianapolis Magazine, by peer vote, 1998
Professor of the Year Award, 1996-1997 Department of Ophthalmology, Indiana University School of Medicine, by resident vote, 1997
Heed Ophthalmic Foundation Fellowship, 1995-1996 1996
Alpha Omega Alpha, 1987-1991 The University of California San Francisco, 1991
The Faculty-Alumni Award, 1987-1991 Academic Excellence (given to the highest ranking graduating student), 1991
Summer research grants Oxford, England, 1991
Pescosolido Scholarship (given to a scholar-athlete), 1982-1986 The Harvard College Scholarship and The John Harvard Scholarship (each year for academic achievement and highest distinction), 1986
B.A. in chemistry Magna Cum Laude, 1982-1986 Harvard College, Dean’s list (all semesters), The Carl A, 1986
The Devlin Scholarship (each year)
Dean’s list Harvard College, 1982-1986
Most Compassionate Doctor American Registry
Fellow (FAAO) American Academy of Ophthalmology
Join now to see all

Clinical Trials

A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration Start of enrollment: 2003 May 01
Completed
Phase 3
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration Start of enrollment: 2006 May 01
Terminated
Phase 2
Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis Start of enrollment: 2007 Oct 01
Unknown status
Phase 2
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD Start of enrollment: 2012 Aug 01
Completed
Phase 2
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) Start of enrollment: 2012 Feb 01
Terminated
Phase 2
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD) Start of enrollment: 2012 Nov 01
Completed
Phase 2
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Start of enrollment: 2013 Feb 01
Completed
Phase 1, Phase 2
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Start of enrollment: 2014 Sep 01
Completed
Phase 3
Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
Completed
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy Start of enrollment: 2015 Feb 01
Completed
Phase 2
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301 Start of enrollment: 2017 Dec 13
Completed
Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201 Start of enrollment: 2016 Nov 01
Completed
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO Start of enrollment: 2017 Jan 31
Terminated
Phase 3
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Start of enrollment: 2017 Apr 04
Completed
Phase 3
Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema Start of enrollment: 2017 Jul 11
Completed
Phase 2
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO Start of enrollment: 2018 Mar 05
Terminated
Phase 3
Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD Start of enrollment: 2020 Dec 15
Completed
Phase 1, Phase 2
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO Start of enrollment: 2015 Jan 01
Completed
Phase 2
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Start of enrollment: 2014 Oct 01
Completed
Phase 2
Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema Start of enrollment: 2016 Nov 10
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

39 citations
Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy
Andrew Lloyd, Natalia Piglowska, Thomas A. Ciulla, Sarah Pitluck, Scott J. Johnson
The British Journal of Ophthalmology. 2019-11-01
272 citations
Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema
Peter A. Campochiaro, David M. Brown, Andrew Pearson, Thomas A. Ciulla, David S. Boyer
Ophthalmology. 2011-04-01
511 citations
Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies
Thomas A. Ciulla, Armando G. Amador, Bernard Zinman
Diabetes Care. 2003-09-01

Journal Articles

Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularization after laser treatment in macular degeneration
N. T. Ranson, R. P. Danis, T. A. Ciulla, L. Pratt, British Journal of Ophthalmology, 5:527-9
ARMD, Exudative.
G. M. Comer, T. A. Ciulla, M. H. Criswell, A. Harris;, eMedicine.
Ranibizumab: A Viewpoint.
T.A. Ciulla, Drugs. 67(8):1207-1209
Squalamine lactate for the treatment of age-related macular degeneration.
T.A. Ciulla, A.Oliver, M.J. Gast, Expert Review of Ophthalmology 2(2): 165-175
Therapeutic effects of ranibizumab in neovascular age-related macular degeneration.
T.A. Ciulla, Expert Review of Ophthalmology. 2(5): 679-693
MV-6401, a potent photosensitizer: a review of the current state of photosensitizing agents for the treatment of exudative age-related macular degeneration.
T.A. Ciulla, A. Oliver, G. M. Comer, Drugs of the Future 30(10): 1031-103
Oral administration of the selective COX-2 inhibitor, Lumiracoxib, significantly reduces choroidal neovascular membrane development in the rat laser-trauma model.
M. H. Criswell, W. Z. Hu, T. L. Cornell, A. Otlecz, . P. Danis, G. N. Lambrou, R, T. A. Ciulla, Retina, 25(8):1054-64
Photodynamic Therapy with PhotoPoint Photosensitizer MV6401, Indium Chloride Methyl Pyropheophorbide, Achieves Selective Closure of Rat Corneal Neovascularization and ...
T. A. Ciulla, M. H. Criswell, W. J. Snyder, W. Small IV, British Journal of Ophthalmology, 89:113-9
Complications of Ganciclovir implant surgery in patients with cytomegalovirus retinitis: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial.
J.P. Dunn, M.V. Natta, G. Foster, B. D. Kuppermann, D.F. Martin, A. Zong, D.A. Jabs, Studies of Ocular Complications of AIDS Research Group, Retina, 24:41-50
The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration.
A. Harris, T. A. Ciulla, L. M. Pratt, E. Rechtman, L. Kagemann, , H. C. Piper, H.J. Garzozi, British Journal of Ophthalmology, 87:753-7
Leber’s congenital amaurosis associated with optic disk neovascularization and vitreous hemorrhage
D. Kurz, T. A. Ciulla, American Journal of Ophthalmology, 135:723-5
Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants.
T.A. Ciulla, M.H. Criswell, R. P. Danis, M. Fronheiser, P. Yuan, T. A. Cox, K.G. Csaky, M. R. Robinson, British Journal of Ophthalmology, 87:1032-7
Novel approaches for retinal drug delivery.
D. Kurz, T. A. Ciulla, Ophthalmology Clinics of North America, 3:405-10
Petgaptanib sodium for macular edema secondary to central retinal vein occlusion.
J.J. Wroblewski, J.A. Wells 3rd, A. P. Adamis, R.R. GBuggage, E.T. Cunningham, Jr., M. Goldbaum, D.R. Guyer, B. Katz, M.M. Altaweel, T.A. Ciulla, Archives of Ophthalmology 127(4): 374-80
Localization and fundus angiography of the photosensitizers rose bengal, CASPc, and chlorine6 in the rabbit eye.
R. Haimovici, T. A. Ciulla, J. W. Miller, A. George, T. Hasan, K. T. Schomacker, E. S. Gragoudas, Retina, 1:65-74
Choroidal perfusion perturbations in non-neovascular age-related macular degeneration.
T. A. Ciulla, A. Harris, H. S. Chung, R. P. Danis, L. Kagemann, B. J. Martin, H. J. Garzozi, British Journal of Ophthalmology, 86:209-213
Potential therapeutic application of antisense oligonucleotides inn the treatment of ocular diseases.
R.P. Danis, T.A .Ciulla, S.P. Henry, Expert Opinion: Pharmacotherapeutics, 2:277-91
The relationship between dietary intake, blood, and retinal concentrations of lutein and zeaxanthin in adult volunteers in a Midwest population.
J. Curran-Celantano, B. R. Hammond, T. A. Ciulla, D. A. Cooper, L. M. Pratt, R. P. Danis, American Journal of Clinical Nutrition, 74: 796-802
Transpupillary Thermotherapy for Subfoveal Occult CNVM: Effect on Ocular Perfusion.
T. A. Ciulla, A. Harris, L. Kagemann, R. Maturi, L. McNulty, R.P Danis, Investigative Ophthalmology and Visual Science, 42: 3337-3340
Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies.
T. A. Ciulla, H. C. Piper, M. Xiao, J. L. Wheat, Current Opinion in Ophthalmology, 12:442-449
Delayed suprachoroidal hemorrhage following glaucoma filtration procedures.
S. S. Tuli, D. WuDunn, T. A. Ciulla, L. B. Cantor, Ophthalmology, 108: 1808-1811
Macular Pigment Optical Density Before And After Cataract Extraction.
T. A. Ciulla, B. R. Hammond, C.W. Yung, L. M. Pratt, Investigative Ophthalmology and Visual Science, 42: 1338 - 1341
Antiangiogenic Therapy of Proliferative Diabetic Retinopathy.
R. P. Danis, T. A. Ciulla, M. H. Criswell, L. M. Pratt, Expert Opinion on Pharmacotherapy, 2: 395 - 407
Ocular perfusion and age-related macular degeneration.
T. A. Ciulla, A. Harris, B. J. Martin, Acta Ophthalmologica, 79: 108-115
Intravitreal triamcinolone acetonide inhibits choroidal neovascular membrane formation in a rat model.
T. A. Ciulla, M. Criswell, R. P. Danis, T. Hill, Archives of Ophthalmology, 119: 399 - 404
Join now to see all

Books/Book Chapters

The Massachusetts Eye and Ear Infirmary Residents’ Guide to Ocular Antimicrobial Therapy.
T. A. Ciulla, A. Sullivan-BakerWellesley: A. K. Peters, Ltd
Ophthalmology Clinics of North America, 11, 3: Ophthalmic Imaging and Diagnostics.
Chapter: The use of dye dilution curve analysis in the quantification of indocyanine green angiograms of the human choroid
A. Harris, L. Kagemann, H. S. Chung, T. A. CiullaEditors: R. L. Stamper.W. B. Saunders Company, Philadelphia
Blood Flow in Glaucoma.
Chapter: The use of dye dilution curve analysis in the quantification of indocyanine green angiograms of the human choroid
L. Kagemann, A. Harris, H. S. Chung, T. A. CiullaEnke Publishing
Retina.
Chapter: Retinal and Choroidal Circulation
A. Harris, D. Bingaman, T.A. Ciulla, B. MartinEditors: S.J. Ryan.Mosby, St. LouisEdition 4,
Ophthalmolog.
Chapter: Exudative Age-Related Macular Degeneration
T. A. Ciulla
Ophthalmic Surgery: Principles and Practice.
Chapter: Vitreo-Retinal Surgery, Principles: Age-Related Macular Degeneration
T. A. CiullaEditors: G.L. Spaeth.W. B. Saunders Company, PhiladelphiaEdition 3,
An Atlas of Ocular Blood Flow- Vascular Anatomy, Pathophysiology, and Metabolism.
A. Harris, C. Jonescu-Cuypers, L. Kagemann, T. A. Ciulla, G.KEditors: Krieglstein.Butterworth, Woburn, MA
Ocular Posterior Segment Imaging.
T. A. Ciulla, A. Harris, C. REditors: Regillo.Lippincott Williams and Wilkins, Philadelphia
Ocular Posterior Segment Imaging.
Chapter: Color Doppler Imaging of Retrobulbar Vasculature
T. A. Ciulla, A. HarrisEditors: T. A. Ciulla, A. Harris, C. R. Regillo.Lippincott Williams and Wilkins, Philadelphia
Retina and Optic Nerve Imaging.
T. A. Ciulla, A. Harris, C. R. RegilloLippincott Williams and Wilkins, Philadelphia
Contemporary Perspectives on Clinical Pharamotherapeutics.
Chapter: Pharmacotherapy of Exudative Age-Related Macular Degeneration: An Update
Grant M. Comer, T.A. CiullaEditors: ”, in K. Kohli, M. Gupta, S. Tejwani.. Elsesier, A division of Reed Elsevier India Private Limited, Lajpat Nagar-IV, New Delhi, India
Join now to see all

Abstracts/Posters

How to manage central serous retinopathy.
T. A. Ciulla, Review of Ophthalmology 6: 99-102
Ferris Do Vitamin Supplements Really Prevent Progression of AMD?
T. A. Ciulla, R. Abel, P. S. Bernstein, D. Boyer, F. L, Ocular Surgery News
Antiangiogenesis therapy for exudative age-related macular degeneration.
T. A. Ciulla, Review of Ophthalmology 7: 84-89
New therapies for age-related macular degeneration.
T. A. Ciulla, Clinical Researcher 1: 14-17
Where the AMD Clinical Trials Stand.
T. A. Ciulla, Retinal Insider
Trends in treatment of Diabetic Macular Edema.
T. A. Ciulla, Review of Ophthalmology, 12:92
The role of ocular perfusion in AMD.
T. A. Ciulla, A. Harris, Review of Ophthalmology, 12:48
The role of ocular blood flow in AMD.
T. A. Ciulla, Ocular Surgery News, p. 19-21
Postoperative Endophthalmitis, Cataract and Refractive Surgery.
T. A. Ciulla, p. 16-18
Roundtable: Laser, PD, surgery, corticosteroids can treat POHS.
T. A. Ciulla, E. T. Cunningham, M. Thomas, H. Kaplan, Ophthamology Times, 27:19, p. 10-12
Roundtable: Nutrition and the eye.
R. Able Jr., J. A. Augustin, T. A. Ciulla, M. J. Cooney. R. P. Gallemore, R. B. Roden, L. J. Singerman, G. A. Williams, Ocular Surgery News 20:23, p 24-28
Round Table: Therapeutic Approaches to Diabetic Macular Edema.
T.A. Ciulla, E.T. Cunningham, L.J. Singerman, Ocular Surgery News, p.88
Whitson: Ocular Blood Flow in Glaucoma and Age-related Macular Degeneration: Evidence Based Clinical Applications.
T.A. Ciulla, K.G. Csaky, A. Harris, L. Kagemann, K.S. Kooner, L.R. Pasquale, J.T, Ophthamology Times
Saperstein, American Academy of Ophthalmology, Focal Points: Clinical Modules for Ophthalmologists, Clinicians’ Corner.
T.A. Ciulla, D.A, Advances in the Treatment of Non-Exudative Age-Related Macular Degeneration
Povidone-Iodine Considered Best Endophthalmitis Prophylaxis.
C. Guttman, T.A. Ciulla, Ophthalmology Times
Three Dimensional Retinal Imaging.
T.A. Ciulla, Review of Ophthalmology, 9:74
Pharmacotherapy for Diabetic Retinopathy.
G. Comer, T.A. Ciulla, Review of Ophthalmology, A Clinician’s Guide to Retinal Disease, 10:25
New Perspectives on Age-Related Macular Degeneration.
C.A. Puliafito, T.A. Ciulla, E.S. Gragoudas, A.C. Ho, J.W. Miller, J.M. Seddon, G.A. Williams, Ocular Surgery News
Tornambe, Diagnosis and Management of Cystoid Macular Edema.
T.A. Ciulla, J.S. Heier, P. Kaiser, R.W. Snyder, P, Continuing Medical Education: A Supplement to Ophthalmology Management
Epidemiology and Impact of Diabetic Retinopathy.
T.A. Ciulla, John Hopkins University School of Medicine Advanced Studies in Medicine,
AMD Combination Therapy: Multiple Mechanistic Approaches.
T.A. Ciulla, Review of Ophthalmology
Breakthroughs in Treating Macular Degeneration: An Interview with Thomas A.
P. Perry, Ciulla, M.D., Saturday Evening Post, p. 38-39, 82-84
Preferred Treatment Depends on Severity of AMD.
D.S. Boyer, N.M. Bressler, T.A. Ciulla, J.I. Lim, E. Reichel, S. Schwartz, Ocular Surgery News
Update on Diabetic Retinopathy.
T.A. Ciulla, Diabetes Dialogue
Emerging Anti-VEGF Inhibitors May Improve Vision In Exudative Age-Related Macular Degeneration, In Update On Clinical Trials In Exudative Age-Related Macular Degenerat...
T.A. Ciulla, Peerview Press
Join now to see all

Lectures

Ophthalmology Anatomy and Physiology.
Eli Lilly and Company
Diabetic Retinopathy, Course Syllabus.
Eli Lilly and Company
Evizon-Visudyne Combo Well-Tolerated for AMD.
Ocular Surgery News
Squalamine With PDT Deemed Safe, Tolerable, for AMD in Phase 2 Trial.
Ocular Surgery News
An Introduction to Neuro-Ophthalmology and An Introduction to Ocular Pharmacology.
Massachusetts Eye and Ear Infirmary, Harvard Medical School
Non-infectious Inflammatory Disorders of the Eye and Adnexa.
Massachusetts Eye and Ear Infirmary, Harvard Medical School
Ocular and Adnexal Infections.
Massachusetts Eye and Ear Infirmary
Retina and vitreous service.
Indiana University School of Medicine
Proton therapy
Indiana University School of Medicine
Oxygen independent photosensitization of DNA by rose bengal.
American Society for Photobiology, Los Angeles, CA
Oxygen independent DNA cleavage photosensitized by rose bengal.
American Chemical Society’s 26th Annual College Research Symposium, Boston, MA
Molecular genotyping of the T-cell receptor beta chain in families of multiple sclerosis patients.
Second International Congress of Neuroimmunology, Philadelphia, PA
antibody negative myasthenia gravis patients reduces acetylcholine receptor agonist induced sodium flux into the TE671 cell line.
Western Medical Student Research Forum, Carmel, CA
Embolic frequency and coexisting disease in central retinal artery occlusion.
Multiple Locations, 1993
Peripapillary subretinal hemorrhage: A sign with a nonspecific but limited differential diagnosis.
North American Neuro-Ophthalmology Society Meeting, Durango, CO
Central retinal artery occlusion in rabbit eyes: A realistic animal model using human atheroma.
Association for Research in Vision and Ophthalmology, Sarasota, FL
Serpiginous choroiditis.
Massachusetts Eye and Ear Infirmary Department of Continuing Education: Ocular and Adnexal Infection
Intravitreal toxicity of dental adhesives in the rabbit.
Multiple Locations, 1995
Early and late endophthalmitis after glaucoma filtering surgery.
American Academy of Ophthalmology, Atlanta, GA
Early and late endophthalmitis after glaucoma filtration surgery: The Massachusetts Eye and Ear Infirmary Experience.
Massachusetts Eye and Ear Infirmary Department of Continuing Education: Ocular and Adnexal Infection
Retinal artery vasospasm and the rabbit electroretinogram.
Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL
Diabetic Retinopathy.
Multiple Locations, 1996, 1997, 2002
Age-related macular degeneration.
Multiple Locations, 1997, 1998
Vitraserts and Intraocular Injections.
Indiana University HIV Clinical Conference, Indianapolis, IN
Proton therapy for choroidal neovascular membranes in age-related macular degeneration.
Multiple Locations, 1997
Join now to see all

Other

American Academy of Ophthalmology, Focal Points: Clinical Modules for Ophthalmologists, Clinicians’ Corner.
T.A. Ciulla, D.A. Saperstein, Advances in the Treatment of Non-Exudative Age-Related Macular Degeneration
Weinberger; Anti-VEGF vs. Macular Grid Photocoagulation for Retinal Vein Occlusion.
R. Ehrlich, R. Axer-Stiegel, T.A. Ciulla, A. Harris, D, Retinal Physician
Targeting VEGF, The VEGF Trap Clinical Trials.
T.A. Ciulla, Review of Ophthalmology, 12:50-54
Drug Delivery to the Posterior Segment.
D.K. Kurz, T.A. Ciulla, Retinal Physician, 4(7): 19-23
Squalamine safe, effective when administered with PDT.
L. Charters, T.A. Ciulla, Ophthalmology Times, 31(5): 64
Update on Diabetic Retinopathy.
T.A. Ciulla, Diabetes Dialogue
Preferred Treatment Depends on Severity of AMD.
D.S. Boyer, N.M. Bressler, T.A. Ciulla, J.I. Lim, E. Reichel, S. Schwartz, Ocular Surgery News
Squalamine With PDT Deemed Safe, Tolerable, for AMD in Phase 2 Trial.
T.A. Ciulla, Ocular Surgery News
Evizon-Visudyne Combo Well-Tolerated for AMD.
T.A. Ciulla, Ocular Surgery News
AMD Combination Therapy: Multiple Mechanistic Approaches.
T.A. Ciulla, Review of Ophthalmology
Epidemiology and Impact of Diabetic Retinopathy.
T.A. Ciulla, John Hopkins University School of Medicine Advanced Studies in Medicine
Tornambe, Diagnosis and Management of Cystoid Macular Edema.
T.A. Ciulla, J.S. Heier, P. Kaiser, R.W. Snyder, P, Continuing Medical Education: A Supplement to Ophthalmology Management
New Perspectives on Age-Related Macular Degeneration.
C.A. Puliafito, T.A. Ciulla, E.S. Gragoudas, A.C. Ho, J.W. Miller, J.M. Seddon, G.A. Williams, Ocular Surgery News
Pharmacotherapy for Diabetic Retinopathy.
G. Comer, T.A. Ciulla, Review of Ophthalmology, A Clinician’s Guide to Retinal Disease, 10:25
Three Dimensional Retinal Imaging.
T.A. Ciulla, Review of Ophthalmology, 9:74
Povidone-Iodine Considered Best Endophthalmitis Prophylaxis.
C. Guttman, T.A. Ciulla, Ophthalmology Times
Indiana University Retina Review.
T. A. Ciulla, R. P. Danis
Ocular Blood Flow in Glaucoma and Age-related Macular Degeneration: Evidence Based Clinical Applications.
T.A. Ciulla, K.G. Csaky, A. Harris, L. Kagemann, K.S. Kooner, L.R. Pasquale, J.T. Whitson, Ophthamology Times
Therapeutic Approaches to Diabetic Macular Edema.
T.A. Ciulla, E.T. Cunningham, L.J. Singerma, Ocular Surgery News, p.88
Roundtable: Nutrition and the eye.
R. Able Jr., J. A. Augustin, T. A. Ciulla, M. J. Cooney. R. P. Gallemore, R. B. Roden, L. J. Singerman, G. A. Williams, Ocular Surgery News 20:23, p 24-28
Roundtable: Laser, PD, surgery, corticosteroids can treat POHS.
T. A. Ciulla, E. T. Cunningham, M. Thomas, H. Kaplan, Ophthamology Times, 27:19, p. 10-12
Postoperative Endophthalmitis.
T. A. Ciulla, Cataract and Refractive Surgery, p. 16-18
The role of ocular blood flow in AMD.
T. A. Ciulla, Ocular Surgery News, p. 19-21
The role of ocular perfusion in AMD.
T. A. Ciulla, A. Harris, Review of Ophthalmology, 12:48
Trends in treatment of Diabetic Macular Edema.
T. A. Ciulla, Review of Ophthalmology, 12:92
Join now to see all

Press Mentions

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (Axitinib Injectable Suspension) in Wet AMDFebruary 2nd, 2023
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (Axitinib Injectable Suspension) in Wet AMDFebruary 2nd, 2023
Microinjection via the Suprachoroidal Space: A Review of a Novel Mode of AdministrationNovember 1st, 2022
Join now to see all

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow
American Society of Retina Specialists - ASRS
Fellow
Association for Research in Vision and Ophthalmology
Member
Retina Society
Member
Macula Society
Member
American Society of Gene and Cell Therapy
Member

External Links

Retina Practicehttps://www.vitreousdoctor.com/
American Society of Retina Specialistshttp://www.asrs.org/find-a-specialist/profile/976/Thomas-A-Ciulla
LinkedInhttps://www.linkedin.com/in/thomas-ciulla-md-mba-86a5504